Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. (NASDAQ: FWBI), now operating as Entero Therapeutics, Inc., generates news primarily as a clinical-stage biopharmaceutical company focused on targeted, non-systemic therapies for gastrointestinal (GI) diseases. Company press releases describe a pipeline that has included biologic and small-molecule candidates such as adrulipase, latiglutenase, capeserod, and niclosamide for a range of GI indications.
News coverage for FWBI has highlighted multiple themes. One recurring category involves capital markets and financing transactions, including registered direct offerings and private placements of common stock and warrants, with stated uses of proceeds for working capital and general corporate purposes. These updates often reference shelf registration statements on Form S-3 and the role of placement agents.
Another important news stream relates to clinical and scientific developments. Releases have discussed Phase 2 clinical trial data for latiglutenase in celiac disease, invited papers in peer-reviewed journals, and abstracts accepted for presentation at major conferences such as Digestive Disease Week. These communications describe work on quantitative mucosal scales and serologic diagnostics in celiac disease, as well as the potential role of latiglutenase as an oral biotherapeutic.
Corporate and strategic news items have included the completion of a business combination with ImmunogenX, Inc., bringing latiglutenase into the GI-focused pipeline, and participation in investor and healthcare conferences where management presents the company’s development strategy and anticipated milestones.
Investors following FWBI-related news can use this page to review historical announcements about GI pipeline evolution, scientific publications, financing activities, and corporate transactions associated with the company that transitioned to Entero Therapeutics, Inc.
Entero Therapeutics, formerly First Wave BioPharma, has rebranded to reflect its focus on gastrointestinal (GI) diseases. The company, now trading under the ticker 'ENTO' effective May 17, 2024, is advancing toward a Phase 3 trial for latiglutenase. This lead asset has shown promise in Phase 2 trials for treating celiac disease, a condition with no current approved treatments. The rebranding follows the acquisition of ImmunogenX and aims to align with Entero's mission to address unmet needs in GI health. The Phase 3 trial is expected to commence in early 2025. Entero will also participate in Celiac Awareness Month by partnering with Celiac Journey for a digital display at the Nasdaq Tower in Times Square.
First Wave BioPharma, Inc. is set to raise approximately $1.1 million in gross proceeds through a registered direct offering priced at-the-market. The Company entered into a securities purchase agreement with an institutional investor for the sale of 366,000 shares of common stock at $2.95 per share. Additionally, warrants to purchase up to 732,000 shares will be issued to the investor at $2.70 per share. The offering, facilitated by Roth Capital Partners, aims to bolster the Company's working capital and general corporate purposes.
First Wave BioPharma, Inc. (NASDAQ: FWBI) partners with Celiac Journey for Celiac Disease Awareness Month to host an event at Nasdaq Tower in Times Square. The event aims to raise awareness about celiac disease, advocate for research, and support the 3.3 million individuals in the U.S. impacted by the condition. The company will showcase a digital display and host a photo event featuring celiac disease advocates and experts. CEO James Sapirstein highlights the lack of treatment options for celiac disease and the company's dedication to developing innovative therapies for GI diseases. Co-founder of Celiac Journey, Jax Bari, emphasizes the challenges faced by individuals with celiac disease and the need for improved research funding and alternative treatments. Co-founder Jon Bari stresses the importance of labeling gluten grains for a better quality of life and safety for celiacs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.